Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73:198. https://doi.org/10.1136/annrheumdis-2012-202603.

Article  CAS  PubMed  Google Scholar 

Verrill M, Declerck P, Loibl S, Lee J, Cortes J. The rise of oncology biosimilars: from process to promise. Future Oncol. 2019;15:3255–65. https://doi.org/10.2217/fon-2019-0145.

Article  CAS  PubMed  Google Scholar 

Antman EM, Creager MA, Houser SR, Warner JJ, Konig M, American Heart Association. American Heart Association Principles on the accessibility and affordability of drugs and biologics: a presidential advisory from the American Heart Association. Circulation. 2017;136:e441–7. https://doi.org/10.1161/CIR.0000000000000551.

Article  PubMed  Google Scholar 

Luzzatto L, Hyry HI, Schieppati A, Costa E, Simoens S, Schaefer F, et al. Outrageous prices of orphan drugs: a call for collaboration. Lancet. 2018;392:791–4. https://doi.org/10.1016/S0140-6736(18)31069-9.

Article  PubMed  Google Scholar 

Gasteiger C, Petrie KJ. Moving forward: Implementing health psychology research to improve patient acceptance of biosimilars. Res Soc Adm Pharm. 2022;18:3860–3. https://doi.org/10.1016/j.sapharm.2022.03.009.

Article  Google Scholar 

IQVIA. Insights into the 2023 U.S. pharmaceutical market. 2023. https://www.iqvia.com/locations/united-states/blogs/2023/07/insights-into-the-2023-us-pharmaceutical-market.

IQVIA. Advancing biosimilar sustainability in Europe. 2018. https://www.iqvia.com/insights/the-iqvia-institute/reports/advancing-biosimilar-sustainability-in-europe.

Peng K, Blais JE, Pratt NL, Guo JJ, Hillen JB, Stanford T, et al. Impact of introducing infliximab biosimilars on total infliximab consumption and originator infliximab prices in eight regions: an interrupted time-series analysis. BioDrugs. 2023;37(3):409–20. https://doi.org/10.1007/s40259-023-00589-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barbier L, Simoens S, Soontjens C, Claus B, Vulto AG, Huys I. Off-patent biologicals and biosimilars tendering in Europe—a proposal towards more sustainable practices. Pharmaceuticals (Basel). 2021;14:499. https://doi.org/10.3390/ph14060499.

Article  PubMed  Google Scholar 

Wilking N, Bucsics A, Kandolf Sekulovic L, Kobelt G, Laslop A, Makaroff L, et al. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries. ESMO Open. 2019;4:e000550. https://doi.org/10.1136/esmoopen-2019-000550.

Article  PubMed  PubMed Central  Google Scholar 

Baumgart DC, Misery L, Naeyaert S, Taylor PC. Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities? Front Pharmacol. 2019;10:279. https://doi.org/10.3389/fphar.2019.00279.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Godman B, Hill A, Simoens S, Selke G, Selke Krulichová I, Zampirolli Dias C, et al. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Rev Pharmacoecon Outcomes Res. 2021;21:527–40. https://doi.org/10.1080/14737167.2021.1884546.

Article  PubMed  Google Scholar 

Gershon N, Berchenko Y, Hall PS, Goldstein DA. Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer. Cost Eff Resour Alloc. 2019;17:5. https://doi.org/10.1186/s12962-019-0174-7.

Article  PubMed  PubMed Central  Google Scholar 

Al-Ziftawi NH, Shafie AA, Mohamed Ibrahim MI. Cost-effectiveness analyses of breast cancer medications use in developing countries: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2021;21:655–66. https://doi.org/10.1080/14737167.2020.1794826.

Article  PubMed  Google Scholar 

Tubic B, Marković-Peković V, Jungić S, Allocati E, Godman B. Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: findings and implications. Med Access Point Care. 2021;5:23992026211027692. https://doi.org/10.1177/23992026211027692.

Article  PubMed  PubMed Central  Google Scholar 

Kirchhoff CF, Wang X-ZM, Conlon HD, Anderson S, Ryan AM, Bose A. Biosimilars: key regulatory considerations and similarity assessment tools. Biotechnol Bioeng. 2017;114:2696–705. https://doi.org/10.1002/bit.26438.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Druedahl LC, Almarsdottir AB, Sporrong SK, De Bruin ML, Hoogland H, Minssen T, et al. A qualitative study of biosimilar manufacturer and regulator perceptions on intellectual property and abbreviated approval pathways. Nat Biotechnol. 2020. https://doi.org/10.1038/s41587-020-0717-7.

Article  PubMed  Google Scholar 

Druedahl LC, Kalvemark Sporrong S, van de Weert M, De Bruin ML, Hoogland H, Minssen T, et al. Evolving biosimilar clinical requirements: a qualitative interview study with industry experts and European National Medicines Agency regulators. BioDrugs. 2021. https://doi.org/10.1007/s40259-021-00478-7.

Article  PubMed  Google Scholar 

Farfan-Portet M-I, Gerkens S, Lepage-Nefkens I, Vinck I, Hulstaert F. Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? Eur J Health Econ. 2014;15:223–8. https://doi.org/10.1007/s10198-013-0538-4.

Article  PubMed  Google Scholar 

Moorkens E, Vulto AG, Huys I, Dylst P, Godman B, Keuerleber S, et al. Policies for biosimilar uptake in Europe: an overview. PLoS ONE. 2017;12:e0190147. https://doi.org/10.1371/journal.pone.0190147.

Article  CAS  PubMed  PubMed Central  Google Scholar 

IQVIA. The impact of biosimilar competition in Europe 2021. 2021. https://www.iqvia.com/library/white-papers/the-impact-of-biosimilar-competition-in-europe-2021.

Lyman GH, Balaban E, Diaz M, Ferris A, Tsao A, Voest E, et al. American society of clinical oncology statement: biosimilars in oncology. J Clin Oncol. 2018;36:1260–5. https://doi.org/10.1200/JCO.2017.77.4893.

Article  PubMed  Google Scholar 

Jensen TB, Kim SC, Jimenez-Solem E, Bartels D, Christensen HR, Andersen JT. Shift from adalimumab originator to biosimilars in Denmark. JAMA Intern Med. 2020;180:902–3. https://doi.org/10.1001/jamainternmed.2020.0338.

Article  PubMed  PubMed Central  Google Scholar 

World Health Organization. The selection and use of essential medicines 2023. Executive summary of the report of the 24th WHO Expert Committee on Selection and Use of Essential Medicines. 2023. https://www.who.int/publications-detail-redirect/WHO-MHP-HPS-EML-2023.01.

Moorkens E, Simoens S, Troein P, Declerck P, Vulto AG, Huys I. Different policy measures and practices between Swedish counties influence market dynamics: part 1-biosimilar and originator infliximab in the hospital setting. BioDrugs. 2019;33:285–97. https://doi.org/10.1007/s40259-019-00345-6.

Article  PubMed  PubMed Central  Google Scholar 

Dylst P, Vulto A, Simoens S. Barriers to the uptake of biosimilars and possible solutions: a Belgian case study. Pharmacoeconomics. 2014;32:681–91. https://doi.org/10.1007/s40273-014-0163-9.

Article  PubMed  Google Scholar 

Rémuzat C, Dorey J, Cristeau O, Ionescu D, Radière G, Toumi M. Key drivers for market penetration of biosimilars in Europe. J Mark Access Health Policy. 2017;5:1272308. https://doi.org/10.1080/20016689.2016.1272308.

Article  PubMed  PubMed Central  Google Scholar 

Moorkens E, Simoens S, Troein P, Declerck P, Vulto AG, Huys I. Different policy measures and practices between Swedish counties influence market dynamics: part 2-biosimilar and originator etanercept in the outpatient setting. BioDrugs. 2019;33:299–306. https://doi.org/10.1007/s40259-019-00346-5.

Article  PubMed  PubMed Central  Google Scholar 

Wu Q, Lian Z, Wang X, Cheng H, Sun J, Yu H, et al. Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-evidence from China. Front Pharmacol. 2022;13:1044798. https://doi.org/10.3389/fphar.2022.1044798.

Article  CAS  PubMed  Google Scholar 

Sullivan E, Piercy J, Waller J, Black CM, Kachroo S. Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn’s disease across Germany. PLoS ONE. 2017;12:e0175826. https://doi.org/10.1371/journal.pone.0175826.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Waller J, Sullivan E, Piercy J, Black CM, Kachroo S. Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany. Patient Prefer Adherence. 2017;11:519–30.